Quoin Pharmaceuticals reports 4 of 6 patients improved in NS compassionate use trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
June 16, 2026 8:30 AM EDTFour of Six Patients Participating in the Compassionate Use Program Were Classified as Improved or Significantly Improved from Baseline Assessment Across Key Clinical Endpoints
All Six Patients Are Younger than 10 Years of Age, with the Youngest Being Just 6 Months OldDuration of Treatment To-Date Ranges from 3 Weeks to 15 MonthsNo Treatment Related Adverse Events Reported for All Six Patients Additional Pediatric Patients Enrolling in Program in June and September Quoin Plans a Comprehensive Data Release, including from Ongoing Phase 2 Studies, in the Coming Months... More